NCT07158996View on ClinicalTrials.gov

A Study of Cizutamig in Systemic Sclerosis

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

September 4, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

August 31, 2027

Conditions

Systemic Sclerosis (SSc)

Interventions

DRUG

Biological: cizutamig

Cizutamig will be dosed according to the protocol.

All Listed Sponsors

lead

Ruijin Hospital

OTHER